Nippon Shinyaku Co., Ltd. (TYO:4516)
5,023.00
+700.00 (16.19%)
At close: Dec 5, 2025
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 40.10B JPY in the quarter ending September 30, 2025, a decrease of -0.25%. This brings the company's revenue in the last twelve months to 160.55B, up 4.07% year-over-year. In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B with 8.08% growth.
Revenue (ttm)
160.55B
Revenue Growth
+4.07%
P/S Ratio
2.11
Revenue / Employee
71.58M
Employees
2,243
Market Cap
338.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,213.71B |
| HOYA Corporation | 892.50B |
| Takeda Pharmaceutical Company | 4,417.00B |
| Daiichi Sankyo Company | 1,978.88B |
| Otsuka Holdings | 2,418.53B |
| Astellas Pharma | 2,006.82B |
| Terumo | 1,062.42B |
| Shionogi & | 437.26B |
Nippon Shinyaku News
- 22 days ago - Nippon Shinyaku H1 Net Profit Declines - Nasdaq
- 11 months ago - Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
- 11 months ago - REGENXBIO partners with Nippon Shinyaku for MPS therapies - Seeking Alpha
- 11 months ago - Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
- 1 year ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 1 year ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 1 year ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga